|
1
|
Yang JC, Ahn MJ, Kim DW, Ramalingam SS,
Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, et al:
Osimertinib in pretreated T790M-Positive advanced non-small-cell
lung cancer: AURA study phase II extension component. J Clin Oncol.
35:1288–1296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY,
Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, et al: Outcomes in
patients with non-small-cell lung cancer and acquired Thr790Met
mutation treated with osimertinib: A genomic study. Lancet Respir
Med. 6:107–116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramalingam SS, Yang JC, Lee CK, Kurata T,
Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, et al:
Osimertinib as first-line treatment of EGFR mutation-positive
advanced non-small-cell lung cancer. J Clin Oncol. 36:841–849.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soria JC, Ohe Y, Vansteenkiste J,
Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura
F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated
advanced non-small-cell lung cancer. N Engl J Med. 378:113–125.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thress KS, Paweletz CP, Felip E, Cho BC,
Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et
al: Acquired EGFR C797S mutation mediates resistance to AZD9291 in
non-small cell lung cancer harboring EGFR T790M. Nat Med.
21:560–562. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL and Yang PC: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee JS, Hur JY, Kim HJ, Lee KY and Kim WS:
A case of concurrent de novo C797S and L858R EGFR mutation detected
in stage IA non-small cell lung cancer patient. J Thorac Oncol.
12:e179–e181. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng D, Hu M, Bai Y, Zhu X, Lu X, Wu C,
Wang J, Liu L, Wang Z, Ni J, et al: EGFR G796D mutation mediates
resistance to osimertinib. Oncotarget. 8:49671–49679.
2017.PubMed/NCBI
|
|
10
|
Ercan D, Choi HG, Yun CH, Capelletti M,
Xie T, Eck MJ, Gray NS and Jänne PA: EGFR mutations and resistance
to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res.
21:3913–3923. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Le X, Puri S, Negrao MV, Nilsson MB,
Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E,
Rinsurongkawong W, et al: Landscape of EGFR-Dependent and
-independent resistance mechanisms to osimertinib and continuation
therapy beyond progression in EGFR-Mutant NSCLC. Clin Cancer Res.
24:6195–6203. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Takezawa K, Pirazzoli V, Arcila ME, Nebhan
CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ,
Melnick MA, et al: HER2 amplification: A potential mechanism of
acquired resistance to EGFR inhibition in EGFR-mutant lung cancers
that lack the second-site EGFRT790M mutation. Cancer Discov.
2:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ou SI, Agarwal N and Ali SM: High MET
amplification level as a resistance mechanism to osimertinib
(AZD9291) in a patient that symptomatically responded to crizotinib
treatment post-osimertinib progression. Lung Cancer. 98:59–61.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blakely CM, Watkins TBK, Wu W, Gini B,
Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas
VR, et al: Evolution and clinical impact of co-occurring genetic
alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet.
49:1693–1704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu HA, Suzawa K, Jordan E, Zehir A, Ni A,
Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, et al: Concurrent
alterations in EGFR-Mutant lung cancers associated with resistance
to EGFR kinase inhibitors and characterization of MTOR as a
mediator of resistance. Clin Cancer Res. 24:3108–3118. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Okabe N, Takagi H, Mine H, Fukai S,
Minemura H and Suzuki H: Osimertinib for epidermal growth factor
receptor mutation-positive lung adenocarcinoma that transformed to
T790M-Positive squamous cell carcinoma. J Thorac Oncol.
12:e167–e169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Watanabe K, Fukuhara T, Tsukita Y, Morita
M, Suzuki A, Tanaka N, Terasaki H, Nukiwa T and Maemondo M: EGFR
mutation analysis of circulating tumor DNA using an improved
PNA-LNA PCR clamp method. Can Respir J. 2016:52973292016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schouten JP, McElgunn CJ, Waaijer R,
Zwijnenburg D, Diepvens F and Pals G: Relative quantification of 40
nucleic acid sequences by multiplex ligation-dependent probe
amplification. Nucleic Acids Res. 30:e572002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oxnard GR, Hu Y, Mileham KF, Husain H,
Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, et
al: Assessment of resistance mechanisms and clinical implications
in patients with EGFR T790M-Positive lung cancer and acquired
resistance to osimertinib. JAMA Oncol. 4:1527–1534. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Niederst MJ, Hu H, Mulvey HE, Lockerman
EL, Garcia AR, Piotrowska Z, Sequist LV and Engelman JA: The
allelic context of the C797S mutation acquired upon treatment with
third-generation EGFR inhibitors impacts sensitivity to subsequent
treatment strategies. Clin Cancer Res. 21:3924–3933. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yatabe Y, Takahashi T and Mitsudomi T:
Epidermal growth factor receptor gene amplification is acquired in
association with tumor progression of EGFR-mutated lung cancer.
Cancer Res. 68:2106–2111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao J, Zou M, Lv J, Han Y and Wang G and
Wang G: Effective treatment of pulmonary adenocarcinoma harboring
triple EGFR mutations of L858R, T790M, and cis-C797S by
osimertinib, bevacizumab, and brigatinib combination therapy: A
case report. Onco Targets Ther. 11:5545–5550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jia Y, Yun CH, Park E, Ercan D, Manuia M,
Juarez J, Xu C, Rhee K, Chen T, Zhang H, et al: Overcoming
EGFR(T790M) and EGFR(C797S) resistance with mutant-selective
allosteric inhibitors. Nature. 534:129–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sholl LM, Yeap BY, Iafrate AJ,
Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu
J, et al: Lung adenocarcinoma with EGFR amplification has distinct
clinicopathologic and molecular features in never-smokers. Cancer
Res. 69:8341–8348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dworakowska D, Jassem E, Jassem J, Peters
B, Dziadziuszko R, Zylicz M, Jakóbkiewicz-Banecka J,
Kobierska-Gulida G, Szymanowska A, Skokowski J, et al: MDM2 gene
amplification: A new independent factor of adverse prognosis in
non-small cell lung cancer (NSCLC). Lung Cancer. 43:285–295. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Turke AB, Zejnullahu K, Wu YL, Song Y,
Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L,
et al: Preexistence and clonal selection of MET amplification in
EGFR mutant NSCLC. Cancer Cell. 17:77–88. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Planchard D, Loriot Y, André F, Gobert A,
Auger N, Lacroix L and Soria JC: EGFR-independent mechanisms of
acquired resistance to AZD9291 in EGFR T790M-positive NSCLC
patients. Ann Oncol. 26:2073–2078. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dei Tos AP, Doglioni C, Piccinin S, Sciot
R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD and
Tallini G: Coordinated expression and amplification of the MDM2,
CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol.
190:531–536. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deben C, Deschoolmeester V, Lardon F,
Rolfo C and Pauwels P: TP53 and MDM2 genetic alterations in
non-small cell lung cancer: Evaluating their prognostic and
predictive value. Crit Rev Oncol Hematol. 99:63–73. 2016.
View Article : Google Scholar : PubMed/NCBI
|
